Long-term outcomes after radiofrequency catheter ablation of the atrioventricular node: The experience of a Portuguese tertiary center.

Ablação do nódulo auriculoventricular Atrioventricular node ablation Disritmias supraventriculares Heart failure Insuficiência cardíaca Supraventricular arrhythmias

Journal

Revista portuguesa de cardiologia
ISSN: 2174-2049
Titre abrégé: Rev Port Cardiol (Engl Ed)
Pays: Spain
ID NLM: 101770878

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 24 12 2019
revised: 08 04 2020
accepted: 05 05 2020
pubmed: 11 1 2021
medline: 1 9 2021
entrez: 10 1 2021
Statut: ppublish

Résumé

In patients with supraventricular arrhythmias and high ventricular rate, unresponsive to rate and rhythm control therapy or catheter ablation, atrioventricular (AV) node ablation may be performed. To assess long-term outcomes after AV node ablation and to analyze predictors of adverse events. We performed a detailed retrospective analysis of all patients who underwent AV node ablation between February 1997 and February 2019, in a single Portuguese tertiary center. A total of 123 patients, mean age 69±9 years and 52% male, underwent AV node ablation. Most of them presented atrial fibrillation at baseline (65%). During a median follow-up of 8.5 years (interquartile range 3.8-11.8), patients improved heart failure (HF) functional class (NYHA class III-IV 46% versus 13%, p=0.001), and there were reductions in hospitalizations due to HF (0.98±1.3 versus 0.28±0.8, p=0.001) and emergency department (ED) visits (1.1±1 versus 0.17±0.7, p=0.0001). There were no device-related complications. Despite permanent pacemaker stimulation, left ventricular ejection fraction did not worsen (47±13% vs. 47%±12, p=0.63). Twenty-eight patients died (23%). The number of ED visits due to HF before AV node ablation was an independent predictor of the composite adverse outcome (OR 1.8, 95% CI 1.24-2.61, p=0.002). Despite pacemaker dependency, the clinical benefit of AV node ablation persisted at long-term follow-up. The number of ED visits due to HF before AV node ablation was an independent predictor of the composite adverse outcome. AV node ablation should probably be considered earlier in the treatment of patients with supraventricular arrhythmias and HF, especially in cases that are unsuitable for selective ablation of the specific arrhythmia.

Identifiants

pubmed: 33422375
pii: S0870-2551(20)30498-4
doi: 10.1016/j.repc.2020.05.016
pii:
doi:

Types de publication

Journal Article

Langues

eng por

Sous-ensembles de citation

IM

Pagination

95-103

Informations de copyright

Copyright © 2020 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

Ana Mosalina Manuel (AM)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal. Electronic address: mosalina@live.com.pt.

João Almeida (J)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Paulo Fonseca (P)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Joel Monteiro (J)

Cardiology Department, Funchal Central Hospital, Madeira, Portugal.

Cláudio Guerreiro (C)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Ana Raquel Barbosa (AR)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Pedro Teixeira (P)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

José Ribeiro (J)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Elisabeth Santos (E)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Filipa Rosas (F)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

José Ribeiro (J)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Adelaide Dias (A)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Daniel Caeiro (D)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Olga Sousa (O)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Madalena Teixeira (M)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Marco Oliveira (M)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Helena Gonçalves (H)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

João Primo (J)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Pedro Braga (P)

Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH